Company Overview and News
I came across some interesting results when looking at dividend investing and growth investing that challenged some of my beliefs.
Although stocks have recently given back some of their short-term gains, the market big picture remains within the frame of momentum, which makes for a good environment to look to growth exchange-traded funds (ETFs).
After a prolonged calm period, volatility roared back into the market with the sharp rise in Treasury yields, which led to the bloodbath in the stock market this week. This pushed the major indices into the red territory for the year and in the correction zone from the latest peak.
After a prolonged calm period, volatility roared back into the market with the sharp rise in Treasury yields, which led to the bloodbath in the stock market this week. This pushed the major indices into the red territory for the year and in the correction zone from the latest peak (read: How to Hedge Volatility With ETFs). The initial nervousness came last Friday, when January jobs reports showed the fastest pace of wage growth in more than eight years.
In 3Q17, Jazz Pharmaceuticals (JAZZ) generated revenue of $411.9 million, which reflected a ~10% rise on a year-over-year (or YoY) basis and a 4% rise on a quarter-over-quarter basis.
Edwards Lifesciences (EW) expects to generate sales growth of 9%–10% in 2018. This underlying sales growth range is narrower than the company’s dollar sales guidance of $3.5 billion–$3.9 billion. Foreign exchange is expected to have a minimal impact of 0.5% on the company’s total sales in 2018. Peers Boston Scientific (BSX), Abbott Laboratories (ABT), and Baxter International (BAX) expect to generate sales growth of approximately 6.
On December 6, 2017, Edwards Lifesciences (EW) announced the completion of its acquisition of Harpoon Medical for $100 million in cash on December 1, 2017. Up to $150 million of milestone-based payments are expected to be paid over the next ten years. The acquired business will be added to Edwards Lifesciences’ Surgical Heart Valve Therapy portfolio.
Varian Medical Systems (VAR) is a better-aligned, leaner business with a strong market position after the spin-off of Varex Imaging (VREX) in January 2017. The company is now focused on its core capability: accelerating its position in the cancer-management market. For a discussion on the company’s future potential, read How Is Varian Positioned for 2018 after 2017 Transformation?
Analysts expect Wyndham Worldwide’s (WYN) revenue to rise 4.7% year-over-year (or YoY) to $1.5 billion and its earnings before interest, tax, depreciation, and amortization (or EBITDA) to rise 2.4% to $349.3 million in 2Q17.
Edwards Lifesciences (EW) is one of the leading players in the artificial valve market. EW stock witnessed a declining trend toward the end of 2016 after the company posted disappointing 2Q16 results. However, it has been recovering recently and returned ~26.5% YTD (year-to-date).
BFOR is our top-rated Mid Cap Growth ETF and ERSMX is our top-rated Mid Cap Growth mutual fund.
Chicago, IL – April 21, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include iShares Core S&P Mid-Cap ETF (NYSEARCA: (IJH - Free Report) – Free Report ), iShares Russell Mid-Cap ETF (NYSEARCA: (IWR - Free Report) – Free Report ), Vanguard Mid-Cap Growth ETF (NYSEARCA: (VOT - Free Report) – Free Report ), iShares S&P Mid-Cap 400 Growth ETF (NYSEARCA: (IJK - Free Report) – Free Report ) and Schwab U.
The first quarter was great for the U.S. stock market with the major benchmarks logging in the best quarterly performance in many years. However, the bullish trend seems to be stalling with the rise in volatility and uncertainty as well as fading of Trump trade. This is especially true against the backdrop of feeble data and growing geopolitical tensions. In particular, the latest round of economic data disappointed for the first time since the U.
The first quarter of 2017 was great for the financial world thanks to easing policies and improving health of the economy amid bouts of volatility. This is especially true as the MSCI All-Country World Index logged in the best quarterly gain of more than 6% representing the best start to the year since 2012. Moreover, the S&P 500 notched its best three-month stretch since the fourth quarter of 2015.
Under Armour (UA) is currently struggling to meet investors’ expectations, as it missed analysts’ estimates in 4Q16. The company reported a 12% rise in revenue in the quarter, missing expectations by $100 million. Some of the ETFs holding Under Armour include the Vanguard Mid-Cap Growth ETF (VOT) and the Consumer Discretionary Select Sector SPDR ETF (XLY).
12h - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
12h - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
22h - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...
as of ET